{"Clinical Trial ID": "NCT00930930", "Intervention": ["INTERVENTION 1:", "- Cisplatin and paclitaxel + RAD001", "Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO per day for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO per day for 11 weeks", "Cisplatin: IV", "Everolimus: given orally", "Paclitaxel: given IV", "The venous blood (2-3 tablespoons) will be taken for analysis of germ DNA to complete the correlative studies in the tumour tissue. Blood may be taken at any time before, during, or after completion of the study treatment.", "INTERVENTION 2:", "\u00b7 Cisplatin and paclitaxel + Placebo", "Cisplatin 25 mg/m2 IV per week + placebo PO per day for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV per week + placebo PO per day for 11 weeks", "Cisplatin: IV", "Paclitaxel: given IV", "placebo: given orally", "The venous blood (2-3 tablespoons) will be taken for analysis of germ DNA to complete the correlative studies in the tumour tissue. Blood may be taken at any time before, during, or after completion of the study treatment."], "Eligibility": ["\u2022 Eligibility criteria", "-The maximum number of patients will include two thirds of the patients in arm 1 and one third of the patients in arm 2 (total of 145 patients).", "\u2022 Inclusion criteria:", "Patients must provide informed written consent.", "The patient must be 18 years of age.", "ECOG Performance Status 0-1.", "- Clinical stage II or stage III triple negative (ER and/or PR no staining or weak staining in cells equal to or less than 10% by immunohistochemistry [IHC] and HER2-negative by Herceptest [0, 1+] or FISH) invasive breast carcinoma, confirmed by histological analysis.", "Patients with a measurable residual tumour* at the primary site", "*Measurable disease: any mass which can be measured in a reproducible manner by physical examination, mammography and/or ultrasound and which can be accurately measured in at least one dimension (the longest diameter to be recorded) of 10 mm (1 cm), either in the breast or in the axillary lymph nodes.", "Fresh tissue should be obtained at the inclusion or biopsy of fresh tissue prior to initiation of treatment.", "* Patients who will undergo surgical treatment either by segmental resection or by total mastectomy.", "Patients should have adequate haematological, hepatic and renal function. All tests should be performed within 4 weeks of entry into the study.", "ANC >/=150/mm3", "Number of platelets >/=100 000/mm3", "Creatinine </=1.5X upper limits of normal", "Bilirubine, SGOT, SGPT </=1.5X upper limits of normal*", "* for patients with Gilbert's syndrome, direct bilirubin will be measured instead of total bilirubin.", "The patient should not have had previous chemotherapy for primary breast cancer.", "Patients with a history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer in the past 5 years.", "\u2022 Capable of swallowing and conserving oral medicines.", "Four days before biopsy procedures, patients should be away from medicines that may increase the risk of bleeding (ASA, NSAIDS, Coumadin, heparin products)", "The potential subjects must complete all screening assessments described in the protocol.", "Note: Women of childbearing potential and their male counterparts should use barrier contraception during and for 3 months following protocol treatment.", "Ineligibility criteria", "- Exclusion criteria:", "A locally recidivating breast cancer.", "Pregnant or lactating women.", "Evidence of distant metastatic disease (e.g., lung, liver, bone, brain, etc.)", "Use of CYP3A4 modifiers (Appendix A)", "A serious medical condition which, according to the treating physician, exposes the patient to a high risk of operational mortality.", "\u2022 Malabsorption syndrome, a disease that significantly affects gastrointestinal function, or small stomach or intestine resection.", "Subjects who have been free of disease for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated on site carcinomas are eligible.", "If the patient is considered at risk for exposure to viral hepatitis B or C (i.e., illicit drug use IV, blood transfusion before 1990, body piercing, tattoos, etc.), appropriate tests should be performed (i.e., hepatitis B surface antigen antibodies and hepatitis C antibodies).", "An active or uncontrolled infection requiring parenteral antibiotics.", "Dementia, altered mental condition, or any psychiatric condition that would prohibit understanding or informed consent.", "- Symptomatic neuropathy (Grade 2).", "- Concomitant anticancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormone therapy or any other biological therapy) other than those specified in the protocol.", "- Concomitant treatment with a research officer.", "\u2022 Use an experimental drug within 15 days or 5 half-lives, whichever is longer, before the first randomised dose."], "Results": ["Performance measures:", "Number of patients with a complete pathological response", "The complete pathological response is defined as no residual tumours during histopathological analysis of the breast and axillary content.", "Time limit: at the time of surgery, week 15-18", "Results 1:", "Title of arm/group: Cisplatin and Paclitaxel + RAD001", "Description of the arm/group: Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO per day for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO per day for 11 weeks", "Cisplatin: IV", "Everolimus: given orally", "Paclitaxel: given IV", "The venous blood (2-3 tablespoons) will be taken for analysis of germ DNA to complete the correlative studies in the tumour tissue. Blood may be taken at any time before, during, or after completion of the study treatment.", "Total number of participants analysed: 88", "Type of measurement: Number", "Unit of measure: participants 34", "Results 2:", "Title of the arm/group: Cisplatin and Paclitaxel + Placebo", "Description arm/group: Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks", "Cisplatin: IV", "Paclitaxel: given IV", "placebo: given orally", "The venous blood (2-3 tablespoons) will be taken for analysis of germ DNA to complete the correlative studies in the tumour tissue. Blood may be taken at any time before, during, or after completion of the study treatment.", "Total number of participants analysed: 44", "Type of measurement: Number", "Unit of measurement: participants 17"], "Adverse Events": ["Undesirable Events 1:", "Total: 22/96 (22.92 per cent)", "Anemia 1/96 (1.04%)", "- Lymphopenia 1/96 (1.04%)", "Cardiac/infarction disorders 1/96 (1.04%)", "- Sinus tachycardia 2/96 (2.08%)", "Dehydration 5/96 (5.21%)", "- Conaction 1/96 (1.04%)", "Diarrhoea 5/96 (5.21%)", "Ileus 1/96 (1.04%)", "Nausea 2/96 (2.08%)", "Vomiting 1/96 (1.04%)", "Distal small intestine obstruction 1/96 (1.04%)", "Oedema 1/96 (1.04%)", "2/96 (2.08%)", "Adverse Events 2:", "Total: 6/49 (12.24 per cent)", "Anemia 0/49 (0.00 %)", "- Lymphopenia 0/49 (0.00 %)", "- Cardiac ischemia/infarction 0/49 (0.00 %)", "- Sinus tachycardia 0/49 (0.00 %)", "Dehydration 1/49 (2.04%)", "- Collision 0/49 (0.00 %)", "Diarrhoea 0/49 (0.00 %)", "Ileus 0/49 (0.00 %)", "Nausea 1/49 (2.04%)", "- Vomiting 1/49 (2.04%)", "Distal small intestine obstruction 0/49 (0.00 %)", "Oedema 0/49 (0.00 %)", "- fatigue 0/49 (0.00 %)"]}